1. Home
  2. LYEL vs CIA Comparison

LYEL vs CIA Comparison

Compare LYEL & CIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$9.34

Market Cap

195.8M

Sector

Health Care

ML Signal

HOLD

Logo Citizens Inc. ($1.00 Par)

CIA

Citizens Inc. ($1.00 Par)

HOLD

Current Price

$3.57

Market Cap

174.2M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
LYEL
CIA
Founded
2018
1969
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Life Insurance
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
195.8M
174.2M
IPO Year
2021
1995

Fundamental Metrics

Financial Performance
Metric
LYEL
CIA
Price
$9.34
$3.57
Analyst Decision
Buy
Analyst Count
8
0
Target Price
★ $37.88
N/A
AVG Volume (30 Days)
★ 151.7K
94.4K
Earning Date
11-11-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
$36,000.00
★ $255,616,000.00
Revenue This Year
N/A
$0.22
Revenue Next Year
N/A
$4.28
P/E Ratio
★ N/A
$28.23
Revenue Growth
N/A
★ 4.33
52 Week Low
$7.20
$3.31
52 Week High
$45.00
$6.54

Technical Indicators

Market Signals
Indicator
LYEL
CIA
Relative Strength Index (RSI) 47.13 51.33
Support Level $7.20 $3.36
Resistance Level $15.38 $3.73
Average True Range (ATR) 0.73 0.14
MACD 0.26 0.03
Stochastic Oscillator 76.41 75.68

Price Performance

Historical Comparison
LYEL
CIA

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

About CIA Citizens Inc. ($1.00 Par)

Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States. The company provides insurance benefits to residents in thirty two U.S. states and more than seventy countries through its insurance subsidiaries. The company operates in two business segments namely the Domestic Insurance and International Insurance segments.. The company majority generates revenues from Life Insurance segment. Company operates in USA, Columbia, Taiwan, Venezuela, Ecuador, Argentina, and Others.

Share on Social Networks: